Clinical Study

E4512- A Phase III Double-Blind Trial For Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo For Patients With Tumors Harboring The Anaplastic Lymphoma Kinase (Alk) Fusion Protein

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The purpose of this research is to compare any good and bad effects of using the study drug, crizotinib after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

Criteria:

To Be Eligible: Must Have Alk-Positive Nsclc, Age 18 Or Older, Nonpregnant/Breastfeeding, No Prior Metastatic Cancer Within 5 Years

Keywords:

Lung Cancer, Nsclc, Cancer, Non-Small Cell Lung , E4512

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.